PCRX Stock Cash Flow Statements

Pacira BioSciences Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Pacira BioSciences Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31

operating activities:
net income	-4,847,000	4,812,000	16,041,000	-143,466,000	18,886,000	8,979,000	24,870,000	10,858,000	25,763,000	-19,536,000	-10,102,000	-693,000	19,876,000	6,828,000	-5,130,000	17,660,000	19,081,000	10,369,000	14,515,000	130,119,000	-7,270,000	8,159,000	-4,888,000	-6,087,000	2,730,000	-2,771,000	8,285,000	-640,000	2,564,000	-10,680,000	4,595,000	-7,597,000	-19,743,000	-19,866,000	-3,972,000	-22,165,000	-7,958,000	-3,854,000	-2,498,000	3,086,000	8,000	1,260,000	5,802,000	-3,004,000	-5,037,000	-11,477,000	-11,956,000	-14,784,000	-14,031,000	-23,138,000	-15,745,000	-8,296,000	-11,894,000	-15,283,000	-9,508,000	-8,762,000	-9,775,000
adjustments to reconcile net income to net cash from operating activities:
deferred taxes	752,000	1,397,000	3,508,000	1,115,000	12,535,000	3,463,000	6,601,000	4,914,000	11,442,000	-7,342,000	-10,840,000	702,000	2,164,000	29,000	-2,081,000	5,340,000	5,867,000	1,746,000
depreciation of fixed assets and amortization of intangible assets	27,322,000	21,168,000	21,243,000	20,253,000	18,863,000	18,426,000	18,485,000	18,433,000	19,054,000	19,602,000	30,406,000	20,198,000	20,864,000	20,033,000	13,070,000	5,730,000	4,897,000	4,851,000	5,061,000	5,037,000	4,989,000	4,821,000	5,090,000	5,605,000
amortization of debt issuance costs	849,000	845,000	846,000	840,000	763,000	681,000	685,000	683,000	691,000	937,000	1,443,000	904,000	874,000	1,179,000	778,000	666,000	659,000	651,000		629,000	444,000	439,000
amortization of debt discount	23,000	22,000	22,000	23,000	23,000	24,000	24,000	25,000	28,000	675,000	700,000	695,000	706,000	706,000	5,907,000	5,844,000	5,744,000	5,657,000	5,570,000	5,430,000	3,660,000	3,594,000	3,530,000	3,467,000	3,404,000	3,345,000	3,287,000	3,229,000	3,170,000	3,113,000	3,058,000	3,003,000	2,951,000	1,411,000	1,022,000	1,022,000	1,022,000	1,022,000	1,022,000	1,022,000	1,023,000	1,035,000	1,035,000	1,035,000	1,034,000	1,035,000	1,035,000	1,034,000	1,035,000	855,000
gain on early extinguishment of debt
stock-based compensation	15,472,000	14,553,000	12,266,000	13,230,000	12,524,000	13,151,000	12,420,000	12,530,000	10,955,000	11,990,000	12,677,000	12,682,000	11,544,000	11,189,000	10,890,000	10,785,000	10,461,000	10,110,000	10,896,000	10,954,000	9,223,000	8,847,000	9,189,000	9,244,000	7,783,000	7,434,000	8,186,000	8,107,000	7,047,000	8,385,000	8,194,000	8,663,000	7,344,000	7,400,000	7,732,000	7,361,000	7,665,000	8,490,000	9,728,000	8,827,000	7,296,000	7,517,000	7,623,000	7,687,000	5,537,000	3,975,000	3,286,000	3,777,000	2,225,000	2,225,000	1,469,000	1,039,000	712,000
changes in contingent consideration	-357,000	-2,675,000	1,084,000	-3,244,000	1,509,000	-3,806,000	423,000	2,793,000	-18,258,000	11,618,000	-6,082,000	-1,043,000	-21,280,000	-1,071,000	1,158,000	-1,159,000	139,000	-1,127,000	6,764,000	752,000	1,562,000	-3,874,000	9,345,000
impairment of investment											0
other net (gains) losses	0	-5,887,000
changes in operating assets and liabilities:
accounts receivable	-9,605,000	8,559,000	-12,651,000	4,127,000	-3,141,000	3,917,000	-8,599,000	2,123,000	-5,875,000	5,192,000	-4,926,000	-2,366,000	998,000	4,215,000	-13,504,000	18,382,000	-15,774,000	462,000	-6,902,000	-2,131,000	-5,025,000	8,542,000	-4,957,000	-1,426,000	-375,000	-1,766,000	-3,734,000	1,375,000	-4,438,000	798,000	-4,637,000	446,000	235,000	2,235,000	-3,172,000	1,886,000	-2,750,000	-46,000	64,000	-1,638,000	230,000	-2,145,000	-1,849,000	28,000	-4,576,000	-1,379,000	-4,819,000
inventories	-14,399,000	-8,472,000	-13,417,000	-8,427,000	-6,657,000	7,572,000	-7,833,000	-4,390,000	847,000	3,086,000	735,000	3,789,000	3,074,000	-5,112,000	-1,907,000	-1,945,000	-658,000	43,000	3,893,000	-1,852,000	-7,024,000	-1,370,000	1,941,000	-7,448,000	-4,059,000	1,540,000	-3,684,000	-2,831,000	-2,010,000	1,368,000	-2,299,000	-5,510,000	-3,291,000	967,000	6,198,000	23,440,000	2,828,000	-2,099,000	-5,513,000	-7,363,000	-12,505,000	-7,001,000	-5,601,000	-4,468,000	-3,830,000	193,000	49,000			1,317,000						-106,000	-173,000
prepaid expenses and other assets	-11,524,000	-7,111,000	-1,022,000	-5,029,000	-2,206,000	897,000	-2,653,000	-2,617,000	-2,443,000	-1,926,000	-2,131,000	2,665,000	1,027,000	-4,260,000	235,000	1,851,000	-1,198,000	254,000	-357,000	1,319,000	1,973,000	-3,674,000	-1,434,000	-1,288,000	481,000	-1,644,000	-1,816,000	-1,514,000	1,312,000	-1,210,000	-258,000	1,885,000	-1,202,000	3,051,000	825,000	-4,294,000	3,009,000	-2,917,000	-1,360,000				-751,000	-364,000	-569,000	237,000	-334,000					64,000	366,000
accounts payable	6,880,000	2,464,000	-325,000	637,000	9,748,000	-6,976,000	-1,072,000	-7,695,000	7,055,000	2,628,000	1,591,000	-577,000	-847,000	6,105,000	-9,437,000	-2,981,000	3,507,000	-1,351,000	-2,195,000	2,400,000	-6,385,000	2,868,000	-2,651,000	2,150,000	121,000	-1,442,000	827,000	1,426,000	-2,932,000	106,000																										-298,000	258,000
accrued expenses and income taxes payable	-19,377,000	4,702,000	-826,000	11,185,000	-2,110,000	3,471,000	4,117,000	4,615,000	-5,651,000	-25,120,000	3,703,000	-4,522,000	-9,877,000	-9,161,000	22,485,000	1,106,000	-113,000	-18,027,000	10,455,000	5,014,000	3,232,000	-24,700,000	16,209,000	2,160,000	7,010,000	-5,166,000	5,274,000	2,232,000	5,320,000	-7,623,000
other liabilities	9,823,000	1,082,000	3,909,000	-405,000	-19,000	-771,000	394,000	-238,000	-143,000	421,000	-1,179,000	144,000	409,000	70,000	1,767,000	-1,032,000	737,000	-1,701,000	-797,000	1,382,000	-1,879,000	-1,173,000	-5,904,000	-577,000	-194,000	-51,000	85,000	487,000	434,000	-109,000	-556,000	-1,519,000	-419,000	-1,061,000	-1,097,000	-1,574,000	3,177,000	-419,000	4,796,000	952,000	9,000	29,000	210,000	879,000	985,000	278,000	312,000	203,000	82,000	450,000				-2,170,000	1,405,000	-433,000	1,225,000
net cash from operating activities	12,012,000	35,459,000	33,132,000	53,920,000	53,236,000	49,101,000	47,584,000	44,438,000	43,499,000	19,128,000	42,037,000	42,654,000	29,806,000	30,777,000	23,215,000	60,287,000	30,134,000	12,081,000	46,667,000	39,781,000	-15,624,000	6,208,000	25,904,000	18,354,000	22,763,000	3,499,000	21,220,000	16,629,000	13,710,000	-2,689,000	16,931,000	-2,808,000	3,656,000	6,000	17,349,000	11,684,000	7,541,000	-3,121,000	17,035,000	2,817,000	8,651,000	493,000	13,011,000	8,976,000	8,218,000	-4,736,000	-6,280,000									-10,923,000	-3,987,000
investing activities:
acquisition of gq bio therapeutics gmbh	0	-16,702,000
purchases of fixed assets	-2,697,000	-8,548,000	-2,118,000	-4,092,000	-1,590,000	-2,836,000	-1,798,000	-3,394,000	-3,404,000	-6,565,000	-5,492,000	-5,181,000	-11,735,000	-7,668,000	-9,166,000	-13,076,000	-10,551,000	-13,073,000	-14,408,000	-7,763,000	-8,906,000	-6,724,000	-4,497,000	-1,592,000	-2,052,000	-2,018,000	-2,243,000	-4,453,000	-2,634,000	-5,184,000	-5,076,000	-5,419,000	-5,155,000	-3,616,000	-4,882,000	-3,906,000	-8,868,000	-7,053,000	-9,124,000	-9,604,000	-13,305,000	-9,237,000	-7,112,000	-4,946,000	-6,023,000	-3,808,000
purchases of available-for-sale investments	-5,056,000	-69,629,000	-45,195,000	-101,236,000	-49,726,000	-56,055,000	-25,926,000	-42,173,000	-20,012,000	-49,497,000	-68,259,000	-131,785,000	-32,040,000	-155,601,000	-97,996,000
sales of available-for-sale investments	71,166,000	69,250,000	46,945,000	53,165,000	36,101,000	43,361,000	36,098,000	41,225,000	33,500,000	126,245,000	84,940,000	89,700,000			598,122,000
purchases of debt investments
net cash from investing activities	62,163,000	-25,629,000	-368,000	-52,163,000	-15,215,000	-15,530,000	8,374,000	-4,342,000	7,326,000	66,183,000	11,189,000	-47,516,000	19,161,000	-208,019,000			3,033,000	-55,664,000	-82,317,000	-202,847,000	36,123,000	-28,566,000	-30,795,000	5,625,000	-181,799,000	78,481,000	-123,163,000	94,459,000	59,573,000	-10,293,000	8,699,000	-27,478,000	-61,150,000	-143,836,000	-6,917,000	-13,320,000	-19,642,000	-21,875,000	7,255,000	-6,840,000	-19,483,000	-1,163,000	4,017,000	-101,801,000	-30,574,000	9,019,000	14,599,000
financing activities:
proceeds from shares issued under employee stock purchase plan			934,000	0				-1,000				-1,000				0			1,125,000	0			1,132,000	0			832,000	0			806,000	0			500,000	0			898,000	0
payment of employee withholding taxes on restricted stock unit vests	-5,285,000	-181,000	-77,000	-32,000	-378,000	-4,000
purchase of treasury stock, inclusive of broker fees
proceeds from 2029 convertible senior notes			0	0
repayment of 2024 convertible senior notes			0	0							0	0	0	-192,609,000
repayment of 2025 convertible senior notes			0	0
repayment of term loan a facility	-3,750,000	-2,813,000	-2,812,000	-2,813,000	-2,812,000	-2,813,000		-27,812,000
purchase of capped call transactions			0	0
payment of debt issuance and financing costs			0	0			0	0	0	-1,163,000									0												0	0	0	-11,000,000													0
net cash from financing activities	-57,505,000	-2,994,000	-1,955,000	-2,845,000	24,980,000	-2,817,000	-1,779,000	-27,787,000	440,000	-153,905,000		-7,775,000	-153,657,000	-181,585,000	361,409,000	3,052,000	5,908,000	10,325,000	10,363,000	209,758,000	3,464,000	-1,281,000	-2,020,000	1,423,000	3,737,000	530,000	3,528,000	2,982,000	2,025,000	419,000	2,280,000	2,688,000	2,338,000	216,856,000	1,070,000	769,000	2,381,000	3,041,000	2,172,000	1,823,000	2,657,000	4,047,000	2,736,000	2,381,000	111,794,000	1,964,000	813,000	979,000	1,187,000	86,186,000	250,000			49,130,000	11,000	0	38,017,000
effect of exchange rate changes on cash and cash equivalents
net increase in cash and cash equivalents	16,874,000	6,836,000	30,809,000	-1,088,000	63,001,000	30,754,000					-5,285,000	-12,637,000			451,542,000	28,262,000			-25,287,000	46,692,000	23,963,000	-23,639,000	-6,911,000	25,402,000	-155,299,000	82,510,000	-98,415,000	114,070,000	75,308,000	-12,563,000			-55,156,000	73,026,000				-21,955,000	26,462,000	-2,200,000	-8,175,000	3,377,000	19,764,000	-90,444,000	89,438,000	6,247,000				16,146,000						-31,881,000	33,198,000
cash and cash equivalents, beginning of period	0	276,774,000		0	0	153,298,000		0	0	104,139,000		0	0	585,578,000		0	0	99,957,000		0	0	78,228,000		0	0	132,526,000		0	0	54,126,000		0	0	35,944,000		0	0	56,984,000		0	0	37,520,000		0	0	12,515,000		0	0	10,126,000	0	0	46,168,000		0	0	26,133,000
cash and cash equivalents, end of period	16,874,000	283,610,000		-1,088,000	63,001,000	184,052,000		12,309,000	51,265,000	35,545,000		-12,637,000	-104,690,000	226,751,000		28,262,000	39,075,000	66,699,000		46,692,000	23,963,000	54,589,000		25,402,000	-155,299,000	215,036,000		114,070,000	75,308,000	41,563,000		-27,598,000	-55,156,000	108,970,000		-867,000	-9,720,000	35,029,000		-2,200,000	-8,175,000	40,897,000		-90,444,000	89,438,000	18,762,000		-5,243,000	-17,646,000	26,272,000	-12,736,000	-3,768,000	25,213,000		-11,048,000	-31,881,000	59,331,000
see accompanying condensed notes to consolidated financial statements.
supplemental cash flow information:
cash paid for interest		2,715,000				3,969,000		4,129,000	3,168,000	17,634,000		8,934,000	4,719,000	9,967,000		1,510,000	1,900,000	1,686,000						0	4,097,000	5,000	4,097,000	6,000	0	4,102,000		4,512,000	4,000	2,380,000																							1,175,000
net cash paid (received) for income taxes		286,000
non-cash investing and financing activities:
fixed assets included in accounts payable and accrued liabilities		767,000				607,000		-918,000	136,000	2,252,000		3,032,000	-3,790,000	6,244,000		-3,377,000	1,063,000	7,033,000
goodwill impairment			0
loss on lease terminations
(gain) loss on early extinguishment of debt			0	0
impairment of indefinite-lived intangible asset
other net incomees					36,000	73,000
payment of contingent consideration														-32,000,000													-1,000	-2,127,000	-2,422,000	-2,293,000	-2,241,000	-2,013,000	-2,114,000	-2,092,000	-2,067,000	-9,919,000	-1,967,000	-1,904,000	-1,992,000	-1,765,000	-1,742,000	-1,620,000	-1,713,000	-9,528,000	-1,193,000	-999,000	-790,000
purchases of debt and equity investments
proceeds from exercises of stock options							0	26,000	1,580,000	333,000	905,000	1,601,000	10,857,000	11,024,000	4,795,000	3,052,000	5,672,000	10,325,000	9,238,000	29,627,000	2,898,000	3,455,000	3,478,000	1,423,000	2,467,000	1,101,000
purchase of treasury stock			0	0
proceeds from term loan a facility								0	0	149,550,000
repayment of 2022 convertible senior notes											0	0							0
repayment of term loan b facility								0	0	-296,875,000
debt extinguishment costs							0	0	0	-5,750,000
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
see accompanying notes to consolidated financial statements.
loss on early extinguishment of debt							0	0	0	16,926,000									0												0	0	11,000	3,721,000													0	0	0	3,398,000
net cash (received) paid for income taxes						-245,000
other losses							-278,000
acquisition of flexion therapeutics, inc.
sale of equity investment															0	0
purchases of equity and debt investments							0	0	-2,758,000	-4,000,000	0	-250,000	0	-12,750,000	0	-2,967,000
proceeds from common stock issued under employee stock purchase plan
proceeds from term loan a facility maturing march 2028
proceeds from term loan b facility maturing december 2026
repayment of term loan b facility maturing december 2026											-59,375,000	-9,375,000
repayment of term loan a facility maturing march 2028
net decrease in cash and cash equivalents								12,309,000	51,265,000	-68,594,000				-358,827,000				-33,258,000																		-867,000
cash paid for income taxes, net of refunds								1,277,000	594,000	201,000		112,000	4,095,000	9,000		812,000	1,446,000	1,000						212,000			-18,000	0			-4,000	0			-6,000	12,000	99,000	142,000
issuance of common stock from conversion of 2022 convertible senior notes												0
loss on disposal of fixed assets																											55,000	0	0	10,000	-6,000	109,000	1,893,000	137,000									1,000	0	149,000	8,000	1,000	0						270,000
loss on investment												76,000	90,000	18,000								3,971,000
(gain) loss on investment										-23,000
gain on disposal of fixed assets											0	0	184,000	9,000
gain on investment and other non-operating income																40,000
proceeds from debt component of the 2025 convertible senior notes																			0
proceeds from equity component of the 2025 convertible senior notes																			0
retirement of equity component of the 2022 convertible senior notes																			0
net cash (used) provided by financing activities
payment of contingent consideration to myoscience, inc. securityholders																0			0	0	-9,145,000	-264,000
(gain) loss on disposal and impairment of fixed assets																	1,000	-11,000
(gain) loss on investment (net of stock dividend) and other non-operating income
changes in operating assets and liabilities
deferred revenue																																		-205,000	-357,000	-356,000	-357,000	-356,000	-357,000	-356,000	-357,000	-356,000	-357,000	-356,000	7,678,000	-252,000	257,000									-533,000	1,000,000
acquisition of myoscience, inc.																							992,000	0
proceeds from term loan b credit facility
repayment of 2019 convertible senior notes																							0	0	0	-338,000					0
conversion premium on 2019 convertible senior notes																							0	0
(gain) loss on disposal of fixed assets
net cash (used in) investing activities
purchases of available for sale investments																	-131,479,000	-186,653,000
sales of available for sale investments																	149,006,000	145,282,000
loss on investment and other non-operating income																		155,000
debt investments																		-1,220,000
amortization of unfavorable lease obligation and debt issuance costs																							434,000	429,000	424,000	420,000	404,000	400,000	395,000	391,000	364,000	360,000	356,000	168,000	120,000	119,000	120,000	120,000	120,000	120,000	119,000	122,000	122,000	122,000	121,000	122,000	122,000	121,000	122,000	94,000
loss on disposal and impairment of fixed assets																			0	0	0	22,000	12,000
purchases of investments																			-219,852,000	-254,401,000	347,000	-72,610,000	-98,393,000	-78,131,000	-119,272,000	-22,688,000	-180,505,000	-1,000	-52,169,000	-130,580,000	-66,735,000	-161,226,000	-94,449,000	-180,342,000	-34,425,000	-36,600,000	-53,947,000	-67,843,000
sales of investments																			153,103,000	59,317,000	44,682,000	50,768,000	71,103,000	85,348,000	59,830,000	103,187,000	59,586,000	101,040,000	116,798,000	127,764,000	97,751,000	141,180,000	40,568,000	42,214,000	34,457,000	37,105,000	45,140,000	54,925,000
equity investment																							0	0
reversal of deferred tax valuation allowance
(gain) loss on investment and other non-operating income
conversion premium on the 2019 convertible senior notes
gain on investment
payment of contingent consideration to myoscience, inc securityholders																					-855,000	-4,736,000
net increase in contingent consideration liabilities																								0
net decrease in accrued fixed assets																					-692,000	-423,000				-37,000
loss on investment (net of stock dividend) and other non-operating income
proceeds from issuance of 2022 convertible senior notes
costs for conversions of convertible senior notes
net increase in accrued fixed assets																								2,345,000			32,000	-2,162,000	2,265,000	-233,000	-865,000	760,000	1,115,000	1,179,000	-604,000	477,000	-2,216,000	1,554,000
depreciation of fixed assets																										3,600,000		3,504,000	2,848,000	2,762,000
conversion premium on convertible senior notes																										-233,000
depreciation of fixed assets and amortization of intangibles																															3,659,000	3,361,000	3,709,000	3,104,000	3,260,000	3,278,000	3,216,000	3,165,000	3,119,000	2,830,000	2,783,000	2,743,000	2,707,000	2,392,000	2,333,000	2,603,000
loss on unexercised investment purchase option																											0
issuance of common stock from conversion of 2019 convertible senior notes																															0	0	494,000	120,466,000
retirement of equity component of 2019 convertible senior notes																															0	-2,000	-515,000	-125,811,000
proceeds from exercise of stock options																												2,982,000	1,073,000	419,000	1,474,000	2,691,000	1,761,000	852,000		769,000	1,390,000	3,041,000				4,047,000										230,000	153,000	124,000	11,000	0	1,000
proceeds from 2022 convertible senior notes																															0	0	0	345,000,000
costs for conversion of convertible senior notes																															0	-1,000	0	-284,000
restricted cash																																							0	0	0	1,509,000	320,000	339,000	-2,168,000	1,633,000	342,000	-977,000	-998,000	1,523,000			1,299,000			-2,069,000	1,314,000
accounts payable, accrued expenses and income taxes payable																															4,817,000	-6,009,000	11,607,000	-1,056,000	6,401,000	2,967,000
royalty interest obligation																																							0	0	0	-276,000	-329,000	-264,000	-196,000	-181,000	-98,000
cash paid for interest, including royalty interest obligation																																			0	1,926,000	0	1,926,000	0	1,927,000	0	2,297,000	320,000	2,290,000	332,000	2,251,000	343,000	2,311,000	262,000	584,000	1,008,000	1,114,000	1,168,000	1,166,000	1,213,000
repayment of debt																																	-479,000	-117,712,000													0
accrued payment of contingent consideration
equity component of the 2022 convertible senior notes																																		70,930,000
adjustments to reconcile net income to net cash provided byoperating activities:
proceeds from follow-on public offering																																											45,000	0
proceeds from exercise of stock options and warrants																																							1,275,000	1,823,000			1,507,000	2,381,000	1,387,000	1,964,000	813,000	979,000	1,187,000	877,000
conversion of principal and equity component of convertible senior notes																																							-1,000	0
issuance of stock from conversion of convertible senior notes																																							-1,000	0
conversion of principal and premium paid on convertible senior notes																																				0
accounts payable and accrued expenses																																						-6,227,000	7,907,000	-2,984,000	9,334,000	-4,316,000	4,078,000	4,950,000	6,757,000	-1,531,000	3,823,000	3,161,000	3,098,000	162,000
proceeds from convertible senior notes																																															0	0	0	120,000,000
equity component of convertible senior notes																																															0
loss on extinguishment of debt																																								0											0
purchases of short-term investments																																								-32,276,000	-42,984,000	-49,937,000	570,000	-87,418,000	-34,046,000	-18,946,000	-12,185,000
sales of short-term investments																																								36,805,000	38,548,000	59,631,000	12,270,000	11,075,000
purchases of long-term investments																																											2,000	-10,984,000
cash paid for income taxes																																								40,000	-1,000	160,000
purchases of fixed assets accrued but not paid
prepaid expenses and other current assets																																									660,000	372,000
proceeds from sales of fixed assets																																																			0
proceeds from borrowings on long-term debt																																																			0
value of warrants issued with debt																																																			0
sale of short-term investments																																														32,772,000	31,000,000	23,764,000	12,050,000	18,750,000
supplemental cash flow information
noncash investing and financing activities:
depreciation and amortization																																															1,700,000	1,330,000	1,286,000	1,431,000	1,417,000	1,405,000	1,380,000	1,284,000	1,029,000	1,011,000	990,000
impairment of long-lived assets
purchase of fixed assets																																																								-1,203,000	-832,000
proceeds from initial public offering																																																						0	0	0	38,016,000
proceeds from offering																																																			0
initial public offering costs paid in 2010																																																						0	0
non cash investing and financing activities:
conversion of notes to common stock																																																						0	0	0	51,222,000
conversion of preferred stock to common stock																																																						0	0	0	6,000
value of equity premium on convertible senior notes																																																	0	24,936,000
amortization of unfavorable lease obligation and deferred financing costs
amortization of end of term fee and warrants																																																			261,000
accounts receivable, net of allowances
net purchases of short-term investments
amortization of deferred financing costs and unfavorable lease obligation
amortization of note discounts and warrants																																																					103,000	104,000	249,000	98,000	1,193,000
change in royalty interest obligation																																																								-816,000	-76,000
trade accounts receivable																																																					1,253,000			755,000	-619,000
proceeds from sale of short-term investments																																																					371,000
financing costs
proceeds from sale of fixed assets
purchase of short-term investments
proceeds from secondary offering
proceeds from convertible notes
proceeds from secured promissory notes and credit facility
payoff of credit facility
accrual for repurchase of intangibles
accrued fixed asset purchase
value of warrants issued with debt and beneficial conversion feature
value of warrants issued to landlord
accrued financing cost
share-based compensation																																																							442,000	551,000	972,000
proceeds from secured promissory notes
proceeds from credit facility
amortization of other assets and unfavorable lease obligation																																																								-72,000	93,000
deferred rent																																																								8,000	13,000
other current assets																																																									-402,000
initial public offering issuance costs paid in 2010																																																									907,000
impairment loss
proceeds from issuance of preferred stock
proceeds from exercise of stock options and issuance of common stock
accrued fixed asset purchases

We provide you with 20 years of cash flow statements for Pacira BioSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Pacira BioSciences stock. Explore the full financial landscape of Pacira BioSciences stock with our expertly curated income statements.

The information provided in this report about Pacira BioSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.